Massachusetts Financial Services’s Ultragenyx Pharmaceutical RARE Stock Holding History

Massachusetts Financial Services’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.11M	Buy	272,882 +12,497	+5%	+$310K	﹤0.01%	769
2026 Q1	$5.46M	Sell	260,385 -49,723	-16%	-$1.12M	﹤0.01%	751
2025 Q4	$7.13M	Sell	310,108 -191,055	-38%	-$6.28M	﹤0.01%	729
2025 Q3	$15.1M	Buy	501,163 +14,531	+3%	+$436K	﹤0.01%	663
2025 Q2	$17.7M	Sell	486,632 -15,391	-3%	-$555K	0.01%	630
2025 Q1	$18.2M	Buy	502,023 +1,306	+0.3%	+$54.3K	0.01%	605
2024 Q4	$21.1M	Sell	500,717 -41,656	-8%	-$2.07M	0.01%	596
2024 Q3	$30.1M	Buy	542,373 +172,126	+46%	+$8.77M	0.01%	538
2024 Q2	$15.2M	Buy	370,247 +103,280	+39%	+$4.41M	﹤0.01%	604
2024 Q1	$12.5M	Buy	+266,967	New	+$12.6M	﹤0.01%	612

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Massachusetts Financial Services's RARE Position: Q2 2026 in Review

Massachusetts Financial Services increased its Ultragenyx Pharmaceutical (RARE) stake by 4.8% in Q2 2026, buying an estimated $310K and bringing the position to 272,882 shares worth $9.11M. The position accounts for ﹤0.01% of the portfolio, ranked #769.

Massachusetts Financial Services first reported a position in RARE in Q1 2024 and has held it in 10 quarters since. The position peaked at $30.1M in Q3 2024. 99 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Massachusetts Financial Services held 272,882 shares of Ultragenyx Pharmaceutical worth $9.11M as of Q2 2026.
Massachusetts Financial Services bought 12,497 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $310K.
Ultragenyx Pharmaceutical made up ﹤0.01% of Massachusetts Financial Services's portfolio in Q2 2026, its #769 holding.
Massachusetts Financial Services first reported a position in Ultragenyx Pharmaceutical in Q1 2024 and has held it in 10 quarters since.
Massachusetts Financial Services's Ultragenyx Pharmaceutical position peaked at $30.1M in Q3 2024.
99 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Massachusetts Financial Services's 13F filing for Q2 2026, filed 3 Aug 2026.